CJC-1295 w/DAC 2mg

A freeze-dried reference material intended solely for non-clinical laboratory evaluation.

Applications: Analytical, in-vitro, and system-development workflows.

Form: Lyophilized powder (2mg)

🔬 CJC-1295 with DAC — Overview

CJC-1295 with DAC (also abbreviated DAC:GRF) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that has been chemically modified with a Drug Affinity Complex (DAC) to significantly extend its half-life in biological systems. This modification allows the peptide to bind to plasma albumin, resulting in prolonged circulation time and sustained stimulation of growth hormone (GH) release — which in turn can elevate IGF-1 levels in research contexts.

📌 Brief Functional Description

• Long-acting analog of GHRH (growth hormone-releasing hormone) designed to stimulate the pituitary gland.
• DAC (Drug Affinity Complex) extends the peptide’s stability and half-life by promoting albumin binding.
• Studied in research and early clinical studies for growth hormone and IGF-1 release kinetics, with implications for metabolism, tissue repair pathways, and endocrine research.
• Not approved as a therapeutic drug; typically labeled for research use only in peptide catalogs.

🧪 Chemical & Structural Information

🔢 CAS Number

• 863288-34-0 — the widely used CAS number for CJC-1295 with DAC in research materials.

🧬 Molecular Formula

• C₁₅₂H₂₅₂N₄₄O₄₂ — the standard elemental composition for the DAC-modified peptide.

⚖️ Molecular Weight

• ≈3,367.9 g/mol (Da) — approximate peptide mass for the DAC-equipped form.
  (Some sources list slightly different values depending on how the DAC modifier is counted or whether water molecules are included; typical quoted range is ~3,647 Da in some catalogs with full DAC side chain. )

🧬 Amino Acid Sequence & Structure

• CJC-1295 with DAC is a modified peptide based on a growth hormone-releasing factor (GHRH) sequence with amino acid substitutions and a maleimidopropionyl-linked DAC group attached via a lysine residue near the C-terminus.
• Typical sequence format begins with: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-… and continues through the modified domain including the DAC attachment.
• The DAC moiety (Drug Affinity Complex) is a chemical extension that promotes albumin binding and reduces proteolytic breakdown.

🧠 Mechanism & Research Context

• CJC-1295 with DAC acts by binding to GHRH receptors in the anterior pituitary, stimulating natural growth hormone release and increasing circulating IGF-1 levels in research models.
• The DAC modification allows the peptide to resist rapid degradation, giving it a much longer effective half-life (several days) compared with shorter GHRH analogs lacking DAC.
• Because of this prolonged action, it’s used in experimental settings to study endocrine signaling kinetics, GH axis modulation, and GH/IGF-1 related pathways.

⚠️ Safety & Regulatory Notes

• Not approved by regulatory agencies (e.g., FDA) as a drug; typically sold as a research peptide.
• Clinical and rigorous human data are limited relative to standard pharmaceuticals, and most safety claims are based on early phase, small cohort studies or preclinical models.
• Altered endocrine signaling (GH/IGF-1 axis) may have complex effects in biological systems and should be interpreted within research contexts — not therapeutic recommendations.

🧪 Additional Notes

• DAC = Drug Affinity Complex — a defined structural addition that interacts with albumin and extends peptide half-life compared with the same peptide without DAC (sometimes called Mod GRF 1-29).
• CJC-1295 peptides (both with and without DAC) are widely discussed in research and biohacking communities but lack broad clinical validation for many claimed benefits.

Notice: For Research Use Only. Not for human or veterinary use.